TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Analyst Sees Strong Medtronic Momentum Through 2026 With Buy Rating Intact

Benzinga Logo Benzinga By Vandana Singh
Analyst Sees Strong Medtronic Momentum Through 2026 With Buy Rating Intact

Bank of America maintains a Buy rating for Medtronic, expecting over 5% revenue growth in fiscal Q2 and strong momentum through 2026, with potential expansion in cardiac ablation solutions and renal denervation.

Insights
META   neutral

Mentioned as having a lower P/E ratio compared to Alphabet, but no specific performance details discussed


MDT   positive

Analyst expects strong revenue growth, raised fiscal year guidance, potential FDA clearance for new technologies, and positive outlook on renal denervation market